AUM Cardiovascular Develops Technology to Help Rule-Out Coronary Artery Disease using AT&T Connectivity
IoT Technology Speeds Test Results
AUM CardiovascularTM, the maker of a handheld device with advanced analytics to help rule-out coronary artery blockages, uses Internet of Things (IoT) global connectivity provided by AT&T* to deliver diagnostic test results to patients in about 10 minutes. Undetected, severe blockage can lead to a heart attack – and in some instances, sudden death.
The CADence™ device, designed and manufactured by AUM Cardiovascular, is a quick, noninvasive, no needle, zero-radiation test. The device uses sophisticated acoustic detection and analysis — a very exciting new method that looks for Coronary Artery Disease (CAD) risk factors in patients by the sound of blood flow in the coronary arteries.
The CADence handheld device collects heart sound data on 4 locations of the patient’s chest. A tablet with an app custom built to work with AT&T’s wireless services receives data from the device. The AT&T Global SIM card sends the data in a highly secure manner to AUM's secure server for acoustic analysis.
Within about 10 minutes of the data upload, the clinician receives the results via email. The entire process takes about 20 minutes.
The process, typically quick and painless for patients, can be performed in the doctor's office, hospital, home or virtually anywhere cellular coverage is available. CADence’s convenience and ease-of-use makes it useful for a wide variety of clinicians including cardiologists, family and internal medicine doctors, nurse practitioners, nurses and certified medical assistants.
“My husband, Rob, fell victim to undetected coronary artery disease at the age of 41. I know firsthand the devastation this disease can cause,” said AUM Cardiovascular Founder and CEO, Marie Johnson, PhD. “We are using the latest technology and AT&T global connectivity to quickly and easily determine if CAD risk factors are present. We hope to prevent tragedy for other families.”
CADence is currently available in Germany. The company is looking to expand to other EU countries and Australia later this year, and Canada and the Philippines in 2017.
CADence is currently under review by the FDA for clearance in the U.S. CADence is expected to be in the U.S. market by the end of 2017, pending FDA approval.
To learn more about IoT’s potential to transform business, visit www.att.com/iot.
For more information on AUM Cardiovascular, visit www.aumcardio.com.
*AT&T products and services are provided or offered by subsidiaries and affiliates of AT&T Inc. under the AT&T brand and not by AT&T Inc.
About AUM Cardiovascular
AUM Cardiovascular is a private cardiovascular diagnostic medical device company located in Northfield, Minnesota. AUM is dedicated to eradicating needless death due to heart disease, a condition suffered by people all over the world.
AT&T Inc. (NYSE:T) helps millions around the globe connect with leading entertainment, mobile, high speed internet and voice services. We’re the world’s largest provider of pay TV. We have TV customers in the U.S. and 11 Latin American countries. We offer the best global coverage of any U.S. wireless provider.* And we help businesses worldwide serve their customers better with our mobility and highly secure cloud solutions.
Additional information about AT&T products and services is available at http://about.att.com. Follow our news on Twitter at @ATT, on Facebook at http://www.facebook.com/att and YouTube at http://www.youtube.com/att.
© 2016 AT&T Intellectual Property. All rights reserved. AT&T, the Globe logo and other marks are trademarks and service marks of AT&T Intellectual Property and/or AT&T affiliated companies. All other marks contained herein are the property of their respective owners.
*Global coverage claim based on offering discounted voice and data roaming; LTE roaming; voice roaming; and world-capable smartphone and tablets in more countries than any other U.S. based carrier. International service required. Coverage not available in all areas. Coverage may vary per country and be limited/restricted in some countries.